Project Details
| Status | Active |
|---|---|
| Effective start/end date | 07/24/25 → 09/26/26 |
Funding
- Anthos Therapeutics Incorporated: $13,280.00
LILAC: A Phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaLuate the effIcacy and safety of abeLacimab in high-risk patients with Atrial fibrillation...
- Rashba, Eric (PI)
- Almasry, Ibrahim (CoPI)
- Fan, Roger (CoPI)
- Singh, Abhijeet (CoPI)
Project: Research